Investing.com — Actinium制药公司（NYSE AMERICAN: ATNM），一家专注于靶向放射治疗的公司，已从Eckert & Ziegler获得了放射性同位素锕-225（Ac-225）的供应，旨在推进其国内外癌症治疗的临床试验。

Actinium Pharmaceuticals Inc. has unveiled ATNM-400, a novel non-PSMA-targeting, first-in-class radiotherapy for prostate cancer utilizing the Actinium-225 (Ac-225) radioisotope.

Title: ATNM-400 is a novel Actinium-225 antibody radioconjugate with strong efficacy in preclinical models of prostate cancer ...

The development of advanced radiotherapy technologies has, in turn, resulted in an increased complexity of operations. Also, a high level of accuracy is needed at every step of the process to achieve ...

Actinium announced ATNM-400, a novel, non-PSMA targeting, first in class radiotherapy for prostate cancer utilizing the Actinium-225 ...

commented: "We believe that targeted radiation therapy with Actinium-225 is one of the most promising approaches for treating patients with myeloid malignancies and solid tumors. As we have ...

ATNM-400 is a first-in-class Actinium-225 (Ac-225) radiotherapy that does not target PSMA, potentially offering an alternative for patients inadequately served by existing treatments. Initial ...

Sandesh Seth, Actinium's Chairman and CEO ... which we believe is due to the precise and potent cell-killing of Ac-225. We are also highly excited by the results of our biodistribution studies ...

Actinium Pharma inks research pact with Memorial Sloan Kettering to support further clinical expansion of Actimab-A's backbone therapy strategy: New York Saturday, March 22, 2025, ...

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it has entered into an agreement for the supply ...

Actinium holds 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. This press release may contain projections or other ...

Sandesh Seth, Actinium's Chairman and CEO, said, "The current era of radiotherapy is built on ... which we believe is due to the precise and potent cell-killing of Ac-225. We are also highly excited ...